Basic Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 458-474
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.458
Table 1 Sequences of primers used in this study
NamePrimer sequence (5’ to 3’)
ZNF710-AS1-201-FACCGCAGGCACTTTGAAGA
ZNF710-AS1-201-RAAGGGACATCAGAGGGGAG
Bcl-2-FGGTGGGGTCATGTGTGTGG
Bcl-2-RCGGTTCAGGTACTCAGTCATCC
Bax-FCCCGAGAGGTCTTTTTCCGAG
Bax-RCCAGCCCATGATGGTTCTGAT
ZNF710-FAACAGGAGGTCTATGAGGTTTCT
ZNF710-RCGCTGAGGTCGATCATCTTGA
IDH2-FCGCCACTATGCCGACAAAAG
IDH2-RACTGCCAGATAATACGGGTCA
SEMA4B-FGAGCGGCCATTCCTCAGATTC
SEMA4B-RCACCCACGTACAGGGTCCT
ARHGAP10-FCCCAGCGGAAGTTTGCTCAT
ARHGAP10-RACAGCTCCAAGTTGCTCTTTTC
RGMB-FCCAGCCCAATGTCGAATCCA
RGMB-RGGTCACTGATACCCAACACGG
miR-93-5p-FCGCAAAGTGCTGTTCGTGC
miR-93-5p-RAGTGCAGGGTCCGAGGTATT
ZNF710-AS1-202-FGTCCGATCACAGTTCACTAC
ZNF710-AS1-202-RATACCAAACCAGGCAACATA
Table 2 Comparison of the clinical features of patients between the low- and high-expression groups, mean ± SD
FeaturesZNF710-AS1-201
P value
Low expression (n = 34)
High expression (n = 34)
Age, yr65.62 ± 6.8567.85 ± 8.250.228
Sex, male (%)19 (55.9)22 (64.7)0.457
CEA, U/mL18.32 ± 69.9611.09 ± 24.580.4151
Neutrophil count, × 109/L3.56 ± 0.974.67 ± 2.080.0061,a
Lymphocyte count, × 109/L1.89 ± 0.621.42 ± 0.47< 0.001a
Monocyte count, × 109/L0.38 ± 0.180.44 ± 0.240.240
Differentiation degree, III-IV (%)18 (52.9)26 (76.5)0.042a
T stage, III-IV (%)15 (44.1)28 (82.4)0.001a
Lymphatic invasion, positive (%)15 (44.1)24 (70.6)0.044a